Pfizer receives positive opinion from CHMP for its smoking cessation pill Champix

By Lisa Kerner

Charlotte, N.C., July 28 - Pfizer Inc. said the Committee for Medicinal Products for Human Use of the European Medicines Evaluation Agency issued a positive opinion recommending marketing authorization of Champix (varenicline), a novel pill for the treatment of smoking cessation.

Champix is believed to work by reducing the severity of the smoker's craving and many withdrawal symptoms from nicotine, according to a company news release.

"Globally, it is expected that half a billion people alive today will die from smoking-related causes," chief medical officer Joseph Feczko said in a company news release.

"Champix represents a significant new discovery in the arena of smoking cessation research."

Varenicline, with the U.S. trade name Chantixline, was approved by the Food and Drug Administration as an aid to smoking cessation in May.

Pfizer is a New York City-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.